Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1

Deborah Higgins, Roberto Rodriguez, Robert Milley, Jason Marshall, Christi Abbate, Tracy dela Cruz, Kathryn Patton, Fiona Walker, Kristin Chichester, Joseph Eiden, Stephen Tuck, Gary Van Nest

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Immunostimulatory DNA sequences (ISS) are potent immunomodulators that can drive TH1 responses to antigens or allergens. This effect can be dramatically enhanced by direct linkage of ISS to the protein. Objective: Evaluate the effects of the number of ISS bound to the major ragweed allergen Amb a 1 on immunogenicity and allergenicity. Methods: Immunogenicity in mice and allergenicity using PBMC or sera from subjects with ragweed allergy were assayed. Results: Both antibody induction in vivo and antibody recognition in vitro were highly sensitive to the number of ISSs linked. IgE recognition of Amb a 1 in competitive ELISA or histamine release assays was inhibited by ISS linkage and showed an inverse relationship to the number of ISSs bound. Type and magnitude of antibody induction in mice was also highly dependent on the number of ISS bound. At the highest ISS to protein ratios, antibody induction was very low. Moderate ISS to protein ratios induced high antibody responses in which IgG2a generally predominated. Low ISS to protein ratios produced the highest overall antibody responses in which IgG1 predominated. In contrast, varied ISS to protein ratios did not affect T-cell responses. In both in vivo mouse studies and in vitro human PBMC studies, all ISS to protein ratios evaluated induced similar responses represented by high levels of IFN-γ and low levels of TH2 cytokines. Conclusion: Controlling the number of ISS bound to a protein allows manipulation of antibody recognition and induction while retaining the potent TH1 properties of an ISS-linked protein. Clinical implications: Immunostimulatory DNA sequence-linked Amb a 1 conjugate represents a safe, novel therapeutic approach for treating ragweed allergy.

Original languageEnglish (US)
Pages (from-to)504-510
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume118
Issue number2
DOIs
StatePublished - Aug 2006

Keywords

  • Allergy
  • Amb a 1
  • allergy vaccine
  • immunogenicity
  • immunostimulatory oligonucleotide
  • linked
  • ragweed

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1'. Together they form a unique fingerprint.

Cite this